Global CRO Signs Seven-Year TrialOne® Agreement With OmniComm Systems
Fort Lauderdale, FL, Oct. 17, 2018 (GLOBE NEWSWIRE) -- A global provider of drug development and commercialization solutions and services has signed a new agreement extending its relationship with OmniComm Systems, Inc. (OTCQX: OMCM), a leading provider of clinical data management technology, for another seven years. Under the terms of the agreement, the CRO will use OmniComm’s TrialOne eClinical solution to automate early phase studies at one of its U.S.-based clinical research units.
The CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Phase I clinics, because TrialOne enables research organizations to greatly improve the productivity and efficiency of their Phase I clinics.
TrialOne streamlines and automates key processes for early phase clinics, which drive efficiencies and reduce timelines and costs through faster and more directed volunteer recruitment, easy-to-build schedule-based workflows, real-time Bedside Data Collection (BDC), direct data capture from devices, sample processing automation and data processing. The automation reduces workload on clinic staff and improves the clinical trial experience for volunteers.
The browser-based, tablet-compatible system provides an advanced platform for automating clinic operations, complies with FDA 21 CFR Part 11, and supports data standards such as CDISC for faster and easier exporting and reporting of data.
“Each new contract documents TrialOne’s position as the market-leading eSource solution for Phase I clinics,” said Kuno van der Post, Ph.D., OmniComm’s chief commercial officer. “We’re excited to continue building our partnership with this leading CRO.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact InfoKuno van der PostOmniComm Systems, Inc. +1.954.473.1254KvanderPost@omnicomm.com
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
